Ticker

Virax Biolabs is advancing a focused strategy centered on ViraxImmune™ and a U.S. market-entry pathway, which management believes is not reflected in the Company's current public valuation despite its balance sheet strength, debt-free position, recent financing and operational progress. LONDON, April 14, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative…

Virax Biolabs said that Virax Biolabs (UK) Limited, its wholly owned subsidiary, has achieved ISO 13485:2016 and ISO 9001:2015 certification for its quality management system. The certifications were issued by LRQA, a risk management company based in the United Kingdom.

LONDON, March 31, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that Virax Biolabs (UK) Limited, its wholly owned subsidiary, has achieved ISO 13485:2016 and ISO 9001:2015 certification for its quality management system. The certifications were issued by LRQA, with an issue date of 18 February 2026 and an expiry date of 17 February 2029.

Virax Biolabs Group Limited (NASDAQ: VRAX - Get Free Report) was the target of a significant growth in short interest in February. As of February 27th, there was short interest totaling 55,704 shares, a growth of 163.7% from the February 12th total of 21,126 shares. Based on an average daily trading volume, of 224,823 shares, the

Virax Biolabs Group Limited (NASDAQ: VRAX - Get Free Report) saw a large drop in short interest in the month of February. As of February 13th, there was short interest totaling 21,126 shares, a drop of 67.6% from the January 29th total of 65,207 shares. Approximately 0.9% of the shares of the company are short sold.